How Can Foreign Oncology Drugs Get Fast-Track Approval in China?

China has dramatically accelerated its approval pathways for innovative oncology drugs, creating multiple fast-track mechanisms that foreign pharmaceutical companies can leverage to bring cancer treatments to Chinese patients more quickly than ever before. Between 2020 and 2026, the NMPA’s Center for Drug Evaluation (CDE) has consistently reduced median approval times for oncology drugs, with breakthrough therapies now receiving marketing authorization in as little as six to twelve months from submission. For foreign companies developing cancer treatments, understanding how to strategically navigate these expedited pathways is critical for competitive market entry.

The Multiple Fast-Track Pathways Available

China’s drug regulatory framework offers several distinct expedited pathways for oncology drugs, each with different criteria, benefits, and procedural requirements:

1. Breakthrough Therapy Designation (BTD)

The Breakthrough Therapy Designation is the most advantageous fast-track pathway for oncology drugs. Introduced under the 2019 Drug Administration Law and detailed in the 2020 Drug Registration Regulation, BTD is available for drugs that demonstrate significant clinical advantages over existing therapies for life-threatening diseases — a category that includes most advanced cancers.

Benefits of BTD include:

• Intensive CDE guidance throughout drug development, including regular milestone meetings
• Rolling review of application materials, allowing submission of completed modules before the full dossier is ready
• Priority review upon NDA submission, with a target review timeline of 60 to 100 working days
• The possibility of conditional approval based on surrogate endpoints or intermediate clinical endpoints
• Dedicated CDE review team with expertise in the specific oncology therapeutic area

Eligibility criteria: The drug must demonstrate preliminary clinical evidence of substantial improvement over existing therapies on clinically significant endpoints. For oncology drugs, this typically means objective response rate (ORR), progression-free survival (PFS), or overall survival (OS) benefits compared to standard of care, or a favorable safety profile in an indication with high unmet medical need.

2. Conditional Approval Pathway

The conditional approval pathway allows the NMPA to grant marketing authorization for oncology drugs based on surrogate endpoints or intermediate clinical endpoints before the completion of confirmatory trials. This pathway has been particularly important for oncology drugs targeting cancers with no effective treatment options.

Key requirements:

• The drug must address a serious, life-threatening disease (cancer qualifies)
• Clinical data must demonstrate the drug’s efficacy based on surrogate endpoints that are reasonably likely to predict clinical benefit
• The sponsor must commit to post-marketing confirmatory trials to verify clinical benefit
• Conditional approval is valid for five years, after which full approval requires completion of confirmatory studies

Common surrogate endpoints accepted by the CDE for conditional oncology approvals include objective response rate (ORR) in early-line therapies, progression-free survival (PFS) in specific indications, and minimal residual disease (MRD) negativity in hematological malignancies. The CDE has published specific guidelines on acceptable surrogate endpoints for different cancer types.

3. Priority Review

Priority review is available for drugs that address diseases with no effective treatment or offer significant clinical advantages over existing therapies. The priority review pathway reduces the standard NDA review timeline from 200 working days to 60 to 120 working days, depending on the drug’s classification and the quality of the submission package.

Oncology drugs frequently qualify for priority review based on:

• First-in-class mechanism of action targeting a cancer pathway
• Significantly improved efficacy over standard of care in head-to-head trials
• Favorable safety profile enabling treatment in patient populations with limited options
• Addressing a cancer type with high incidence and mortality in China (lung, gastric, liver, esophageal, colorectal)

4. Overseas-Approved Drug Expedited Pathway

Under the 2020 Drug Registration Regulation, oncology drugs that have been approved by the FDA, EMA, or Japan’s PMDA may be eligible for an accelerated review pathway that leverages foreign clinical data. This pathway is specifically designed to reduce duplication of clinical trials and accelerate access to drugs already proven safe and effective in other established regulatory jurisdictions.

Requirements:

• The drug must have received marketing authorization from at least one of the recognized reference authorities (FDA, EMA, PMDA)
• The drug must be intended for a serious or life-threatening disease with no effective treatment in China, or must demonstrate clear clinical advantages over existing therapies
• The sponsor must submit a comprehensive data package including all foreign clinical trial data, with appropriate bridging analysis to the Chinese population
• A China-specific clinical study may be required for drugs with significant ethnic sensitivity, though the CDE has increasingly accepted limited bridging studies or PK comparability data

Ethnic Sensitivity and Clinical Data Requirements

One of the most important considerations for foreign oncology drugs seeking fast-track approval in China is the issue of ethnic sensitivity. The CDE follows guidelines similar to ICH E5 (Ethnic Factors in the Acceptability of Foreign Clinical Data) but applies them with specific considerations for the Chinese population.

Oncology drugs with the following characteristics are more likely to require China-specific clinical data:

• Drugs with metabolism primarily through CYP450 enzymes with known genetic polymorphisms in Asian populations
• Immunotherapies where immune response may vary by ethnicity
• Drugs targeting oncogenic drivers with different mutation frequencies in Chinese versus Western populations (e.g., EGFR mutations in lung cancer, which are significantly more prevalent in Asian patients)
• Drugs with narrow therapeutic windows where small PK differences could significantly impact safety

Conversely, oncology drugs that are more likely to succeed with foreign data alone include:

• Drugs targeting well-conserved biological pathways with no known ethnic variability
• Drugs with wide therapeutic windows and well-characterized PK profiles
• Drugs for ultra-rare cancers where clinical trial enrollment is inherently limited
• Drugs that have demonstrated consistent efficacy across multiple ethnic groups in global trials

Strategic Considerations for Foreign Oncology Companies

Early and Frequent CDE Engagement

The single most important factor in successful fast-track approval is early and frequent engagement with the CDE. The CDE offers a formal pre-submission consultation process, and foreign companies developing oncology drugs should request these meetings at key development milestones:

• At Phase 1 completion to discuss the overall development plan
• At end-of-Phase 2 to discuss the pivotal trial design and surrogate endpoint selection
• Pre-NDA to discuss submission package requirements and review timelines
• During review to address CDE questions and provide supplementary data

Incorporating Chinese Patients in Global Trials

Including Chinese patients in global multicenter oncology trials has become the gold standard for supporting fast-track approval in China. The CDE strongly prefers data from Chinese patients enrolled in global registration trials, and this approach significantly reduces both the time and cost of achieving Chinese market approval. Leading foreign oncology companies now routinely include Chinese clinical trial sites in their global Phase 3 programs, enabling simultaneous global and China submissions.

Targeting China’s High-Burden Cancers

The CDE’s review priorities are influenced by China’s specific cancer epidemiology. Lung cancer (the most common cancer in China), gastric cancer, liver cancer, esophageal cancer, and colorectal cancer represent the highest disease burden. Oncology drugs targeting these indications receive enhanced attention and faster review timelines. Foreign companies developing drugs for these China-prevalent cancers should highlight the public health impact in their BTD and priority review applications.

Preparing a Comprehensive Submission Package

A well-prepared submission package can shave months off the review timeline. Key elements that CDE reviewers evaluate for completeness include:

• Complete quality (CMC) data package manufactured in accordance with NMPA GMP standards
• Comprehensive non-clinical pharmacology and toxicology data, including any China-specific studies
• Well-analyzed clinical data with appropriate statistical methods
• Risk management plan (RMP) tailored to the Chinese healthcare context
• Labeling and patient information in compliant Chinese language

Recent Approval Success Stories

Several foreign oncology drugs have successfully navigated China’s fast-track pathways in recent years, providing valuable precedents. Examples include PD-1/PD-L1 inhibitors that received conditional approval based on Phase 2 data with ORR endpoints; targeted therapies for EGFR-mutant lung cancer that received priority review based on global trial data with Chinese subgroup analysis; and CAR-T cell therapies that received breakthrough therapy designation and conditional approval for hematological malignancies.

These cases demonstrate that the CDE is increasingly aligned with international regulatory practices for oncology drugs while maintaining specific requirements related to Chinese population data and local manufacturing standards. The trend is clear: the CDE has become more pragmatic and efficient in its review of oncology products that address genuine unmet medical needs in the Chinese population.

Post-Marketing Requirements and Lifecycle Management

Foreign companies that receive fast-track approval should be aware of the post-marketing obligations that accompany expedited pathways. Conditional approvals require confirmatory trials to be completed within a specified timeframe, typically three to five years. Sponsors must submit annual reports on the progress of these confirmatory studies, and failure to complete them can result in the NMPA withdrawing marketing authorization. Additionally, pharmacovigilance requirements for fast-track approved drugs are more intensive, with more frequent safety update reports and enhanced adverse event monitoring expectations. Foreign companies should plan their post-marketing commitments carefully, allocating sufficient resources for ongoing clinical development and safety surveillance in China.

Conclusion

China’s fast-track approval pathways for oncology drugs — including Breakthrough Therapy Designation, conditional approval, priority review, and the overseas-approved drug pathway — offer foreign pharmaceutical companies multiple routes to accelerate market access. Success requires a strategic approach that includes early CDE engagement, thoughtful incorporation of Chinese clinical data, careful ethnic sensitivity analysis, and comprehensive submission packages. For foreign oncology companies willing to invest in understanding and navigating these pathways, the Chinese market offers unprecedented opportunities to bring innovative cancer therapies to patients in need, with approval timelines that now rival those of the FDA and EMA for priority products.

Disclaimer: This article provides general guidance and does not constitute legal or regulatory advice. Foreign pharmaceutical companies should consult with qualified regulatory affairs professionals for their specific product development and registration strategies in China.